Noxopharm Ltd (ASX:NOX) has a primary focus on the development of drugs to address the problem of drug-resistance in cancer.
The company is aiming to bring to market NOX66 by 2022, which sensitises most forms of cancer to radiotherapy and chemotherapy and delivers improved survival outcomes for most cancer patients.
Noxopharm has been granted a trading halt this morning by the ASX, pending details of a capital raising.
The halt will remain in place until the opening of trade on Wednesday 23rd August 2017, or earlier if an announcement is made to the market.